15‐Epi‐Lxa 4 and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture
Open Access
- 27 March 2019
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 33 (7) , 8043-8054
Abstract
Resolution of inflammation is poorly understood in Achilles tendon disorders. Herein, we investigated the bioactive lipid mediator profiles of tendon‐derived stromal cells isolated from patients with Achilles tendinopathy (AT) or Achilles rupture (AR) under baseline and IL‐1β–stimulated conditions. We also determined whether incubating these cells with 2 of the mediators produced by tendon‐derived stromal cells, 15‐epi‐Lipoxin A 4 (15‐epi‐LXA 4 ) or maresin (MaR)‐1, moderated their proinflammatory phenotype. Under baseline conditions, AT cells showed concurrent increased levels of proinflammatory eicosanoids and proresolving mediators compared with AR cells. IL‐1β treatment induced profound prostaglandin E 2 release in AR compared with AT cells. Incubation of IL‐1β treated AT and AR tendon‐derived stromal cells in 15‐epi‐LXA 4 or MaR1 reduced proinflammatory eicosanoids and potentiated the release of proresolving mediators. These mediators also induced specialized proresolving mediator (SPM) biosynthetic enzymes arachidonate lipoxygenase (ALOX) 12 and ALOX15 and up‐regulated the proresolving receptor ALX compared with vehicle‐treated cells. Incubation in 15‐epi‐LXA 4 or MaR1 also moderated the proinflammatory phenotype of AT and AR cells, regulating podoplanin, CD90, signal transducer and activator of transcription (STAT)‐1, IL‐6, IFN regulatory factor (IRF) 5, and TLR4 and suppressed c‐Jun N‐terminal kinase 1/2/3, Lyn, STAT‐3, and STAT‐6 Phosphokinase signaling. In summary, we identify proresolving mediators that are active in AT and AR and propose SPMs, including 15‐epi‐LXA 4 or MaR1, as a potential strategy to counterregulate inflammatory processes in these cells.—Dakin, S. G., Colas, R. A., Newton, J., Gwilym, S., Jones, N., Reid, H. A. B., Wood, S., Appleton, L., Wheway, K., Watkins, B., Dalli, J., Carr, A. J. 15‐Epi‐LXA 4 and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture. FASEB J. 33, 8043–8054 (2019). www.fasebj.orgKeywords
Funding Information
- H2020 European Research Council
- Horizon 2020 Framework Programme (677542)
- Wellcome Trust
- Royal Society (107613/Z/15/Z)
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
This publication has 40 references indexed in Scilit:
- Multiple roles of Lyn kinase in myeloid cell signaling and functionImmunological Reviews, 2009
- Genetic Risk Factors for Musculoskeletal Soft Tissue Injuries2009
- Aging enhances a mechanically‐induced reduction in tendon strength by an active process involving matrix metalloproteinase activityAging Cell, 2007
- Achilles Tendon Disorders: Etiology and EpidemiologyFoot and Ankle Clinics, 2005
- Lyn Tyrosine KinaseAccentuating the Positive and the NegativeImmunity, 2005
- Lyn Tyrosine KinaseImmunity, 2005
- Inflammatory Resolution: new opportunities for drug discoveryNature Reviews Drug Discovery, 2004
- Surgical treatment for chronic Achilles tendinopathy: a prospective seven month follow up studyBritish Journal of Sports Medicine, 2002
- The VISA-A questionnaire: a valid and reliable index of the clinical severity of Achilles tendinopathyBritish Journal of Sports Medicine, 2001
- Chronic Achilles TendinosisSports Medicine, 2000